Gregg Yamada, MD
Cardiovascular Disease · Honolulu, HINPI 1821006933
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Amarin Pharma, Inc. accounts for 65.8% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $273 and has fallen 87.3% since, to $35 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in HI, where the typical reported total is $1,979.
Across 26 payments — averaging $29.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$503
- E.r. Squibb & Sons, L.L.C.$168
- Amgen$57
- Regeneron Healthcare Solutions, Inc.$19
- Novartis$17
What the payments were for
- Food & beverage$74598%
- Education$192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 13 | $503 |
| E.r. Squibb & Sons, L.L.C. | 9 | $168 |
| Amgen | 2 | $57 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Novartis | 1 | $17 |
How this compares
$764 in reported general payments places this provider in the 20th percentile of 73 cardiovascular disease providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 647 | $598,409 |
| EliquisApixaban | 352 | $542,156 |
| Praluent PenAlirocumab | 131 | $96,297 |
| XareltoRivaroxaban | 39 | $56,858 |
| VascepaIcosapent Ethyl | 45 | $42,132 |
| Atorvastatin Calcium | 827 | $24,479 |
| Metoprolol Succinate | 711 | $17,821 |
| Ezetimibe | 212 | $14,681 |
| Losartan Potassium | 346 | $8,948 |
| Carvedilol ErCarvedilol Phosphate | 16 | $8,185 |
| Rosuvastatin Calcium | 159 | $7,440 |
| Colesevelam Hcl | 18 | $6,504 |
| Amlodipine Besylate | 325 | $6,401 |
| Nebivolol Hcl | 79 | $5,455 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 94 | $4,750 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Honolulu
- Dipanjan BanerjeeHonolulu$331K
- Joana MagnoHonolulu$23K
- Hingson ChunHonolulu$23K
- William DangHonolulu$16K
- Edward ShenHonolulu$12K
- Se Kon WonHonolulu$11K
- Wesley KaiHonolulu$10K
- Calvin WongHonolulu$8K
- Abdulelah NuqaliHonolulu$7K
- Mahdi Veillet-ChowdhuryHonolulu$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.